Market
Novo Nordisk's global ranking in pharma sector post-Catalent acquisition by 2025
2
Resolution / Starting Odds
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Below Top 20 • 25%
Industry ranking reports from reputable sources like Forbes or Fortune
Story
Novo Nordisk Cleared to Acquire Three Catalent Manufacturing Sites for $CTLT Following FTC Approval
Dec 14, 2024, 08:49 AM
Novo Nordisk has received clearance to proceed with its acquisition of three manufacturing sites from Catalent, following the Federal Trade Commission's decision not to challenge the deal. This acquisition is part of a larger transaction involving Catalent and Novo Holdings, which has also met all regulatory closing conditions. The approval allows Novo Nordisk to enhance its manufacturing capabilities by integrating these sites, thereby strengthening its position in the pharmaceutical sector. The deal has been noted as significant given the current regulatory environment surrounding pharmaceutical acquisitions.
View original story
Similar markets
Below Top 20 • 25%
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Decrease • 25%
Slightly increase • 25%
No change • 25%
Significantly increase • 25%
Outperform slightly • 25%
Outperform significantly • 25%
Underperform • 25%
Match performance • 25%
Top 3 in the sector • 25%
Outside top 5 • 25%
Top 5 in the sector • 25%
Leader in the sector • 25%
Seek further trials • 25%
Discontinue development • 25%
Partner with another company • 25%
Submit for regulatory approval • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
Develop a new obesity drug • 25%
Focus on improving CagriSema • 25%
Pursue mergers or acquisitions • 25%
Increase investment in marketing existing drugs • 25%
